Treatment of Ulcerative Colitis: Maximizing the Benefit to Patients

Miguel D. Regueiro, MD


May 16, 2022

Using an early patient experience as a launching point, Miguel Regueiro, MD, reflects on the gradual shift away from treatments for ulcerative colitis, such as the long-term prescribing of steroids and surgery — both effective but with undesirable side effects — to newer therapies that are more precise in their agency, such as monoclonal antibodies and small molecules.

The resulting benefits to patients, when coupled with a determined integration of social and psychological factors, amount to a practical revolution in ulcerative colitis care over the past three decades.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.